BioArctic Partner Eisai Wins Canadian Reimbursement Recommendation for Alzheimer's Drug

MT Newswires · 3d ago
01:49 AM EDT, 09/01/2026 (MT Newswires) -- BioArctic's (BIOA-B.ST) partner Eisai secured Canada's Drug Agency's final recommendation supporting public reimbursement of Leqembi for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. The Swedish research-based biopharma company will engage with the pan-Canadian Pharmaceutical Alliance to make reimbursements via public drug plans across Canada, according to a Tuesday release.